HF Advisory Group LLC Makes New $622,000 Investment in DexCom, Inc. $DXCM

HF Advisory Group LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 7,205 shares of the medical device company’s stock, valued at approximately $622,000.

A number of other large investors have also modified their holdings of DXCM. Legal & General Group Plc acquired a new position in DexCom during the 2nd quarter worth approximately $173,237,000. Deutsche Bank AG acquired a new stake in DexCom in the second quarter valued at approximately $164,035,000. Employees Provident Fund Board purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $145,352,000. J. Stern & Co. LLP raised its stake in shares of DexCom by 2,114.8% during the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after purchasing an additional 1,529,641 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of DexCom by 15.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock worth $758,487,000 after purchasing an additional 1,515,702 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director directly owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 49,313 shares of company stock valued at $3,945,875. 0.28% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DXCM. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings raised shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $105.00 price objective (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Wall Street Zen raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Sunday, September 6th. Finally, Barclays upgraded DexCom to a “strong-buy” rating in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $91.96.

DexCom Stock Down 0.4%

Shares of DexCom stock opened at $84.11 on Friday. The company has a market capitalization of $31.74 billion, a P/E ratio of 33.25, a PEG ratio of 1.41 and a beta of 1.48. The business’s fifty day moving average price is $87.54 and its two-hundred day moving average price is $75.16. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the prior year, the firm posted $0.48 EPS. DexCom’s revenue was up 13.1% compared to the same quarter last year. As a group, research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.